In conclusion we have demonstrated that the next-generation TNFRSF agonists, the HERA-ligands, are capable of inducing TNFRSF activation, resulting in enhanced inflammatory response in vitro compared to other anti-CD40 agonist mAb such as Selicrelumab, resulting in enhanced tumor control in vivo, in combination with RT therapy. The gene discussed is ERAL1; the disease is neoplasm.